詹啟賢：腸病毒疫苗無不法【聯合報╱記者施靜茹／即時報導】 2013.03.19 08:24 pm 對立委指腸病毒七一型疫苗與大陸疫苗廠簽合作意向書，國光生技公司董事長詹啟賢今天說，和河南華蘭生物工程合約已到期，不會續約。詹啟賢人在日本，今天他接受越洋電話採訪說，和華蘭簽約，「沒有見不得人」，一來未涉及技術轉移；二來合約載明，所有內容都需經雙方政府同意才能進行。【2013/03/19 聯合報】
Vaccine developer, drug company deny cooperating with China 2013/03/18 20:02:13 Taipei, March 18 (CNA) The National Health Research Institutes (NHRI) and a local pharmaceutical company both denied allegations Monday of a cooperation plan with a Chinese bio-engineering company to produce a NHRI-developed vaccine for enterovirus 71 (EV71).Legislator Lin Shih-chia of the opposition Taiwan Solidarity Union said during a hearing at the Legislative Yuan earlier in the day that the Taichung-headquartered Adimmune Co., which has the NHRI's technology transfer for the research and manufacture of EV71 vaccine, signed a letter of intent last year with China's Hualan Biological Engineering Inc. for cooperation in producing vaccines. Questioning Health Minister Chiu Wen-ta about the cooperation plan, Lin argued that epidemic prevention and control concerns the country's public health, which makes it an important national matter. Despite this, she went on, the authorized drug maker has decided to work with a Chinese business."Is this appropriate?" Lin asked, implying a national health risk because the crucial vaccine could possibly be mass-produced in China, which has never relented on its claim that Taiwan is part of its territory.Chiu responded by saying only that he would not comment until after he had studied the case.According to Lin's office, Adimmune and the Henan Province-based Hualan Bio signed the letter of intent March 23 last year. The cooperation situation was soon then published on Hualan's official website, but was never reported on Adimmune's, the office said.NHRI President Kung Hsing-jien told CNA that Adimmune -- the only cGMP manufacturer of human vaccines in Taiwan -- had explained to his institution that what it signed with Hualan was nothing more than a letter of intent and denied it had signed any formal cooperation contract with the Chinese company.Meanwhile, Adimmune spokesman Kao Sheng-kai said the one-year letter of intent is about to expire and that the two sides have since last March had no further interaction with each other on the matter.Adimmune has not broken its contract with NHRI, Kao stressed.Kung explained that under the NHRI-to-Adimmune technology transfer deal, the pharmaceutical company must develop and produce the EV71 vaccine in Taiwan, and in Taiwan only.EV71, which is one of the major causative agents for hand, foot and mouth disease (HFMD), is sometimes associated with severe central nervous system diseases. In 1997 in Malaysia and Japan, and in 1998 in Taiwan, there were HFMD epidemics involving sudden deaths among young children, and EV71 was isolated from the HFMD patients, including the fatal cases. (By Chen Ching-fang and Elizabeth Hsu)
No comments:
Post a Comment